Enovis Co. (NYSE:ENOV) Shares Purchased by Royce & Associates LP

Royce & Associates LP raised its stake in shares of Enovis Co. (NYSE:ENOV - Free Report) by 16.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,403,685 shares of the company's stock after buying an additional 346,317 shares during the period. Enovis accounts for approximately 0.9% of Royce & Associates LP's portfolio, making the stock its 3rd biggest holding. Royce & Associates LP owned 4.30% of Enovis worth $103,479,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ENOV. Janney Montgomery Scott LLC increased its position in Enovis by 18.6% during the first quarter. Janney Montgomery Scott LLC now owns 4,879 shares of the company's stock worth $305,000 after acquiring an additional 765 shares during the period. Envestnet Portfolio Solutions Inc. grew its position in Enovis by 21.0% during the first quarter. Envestnet Portfolio Solutions Inc. now owns 6,272 shares of the company's stock worth $392,000 after buying an additional 1,087 shares in the last quarter. Swiss National Bank increased its stake in Enovis by 0.3% during the first quarter. Swiss National Bank now owns 97,000 shares of the company's stock valued at $6,058,000 after acquiring an additional 300 shares during the period. US Bancorp DE raised its holdings in Enovis by 3.5% in the 1st quarter. US Bancorp DE now owns 13,043 shares of the company's stock valued at $815,000 after acquiring an additional 447 shares in the last quarter. Finally, HBK Sorce Advisory LLC bought a new stake in shares of Enovis in the 1st quarter worth approximately $226,000. 98.45% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts recently commented on ENOV shares. Needham & Company LLC restated a "buy" rating and set a $65.00 target price on shares of Enovis in a research report on Thursday, November 7th. Evercore ISI dropped their price objective on shares of Enovis from $62.00 to $58.00 and set an "outperform" rating for the company in a report on Tuesday, October 1st. JPMorgan Chase & Co. cut their price objective on Enovis from $53.00 to $50.00 and set a "neutral" rating for the company in a research report on Thursday, August 8th. Finally, JMP Securities initiated coverage on shares of Enovis in a research report on Thursday, October 3rd. They set an "outperform" rating and a $62.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, Enovis currently has an average rating of "Moderate Buy" and a consensus price target of $67.00.

Enovis Stock Performance

Shares of ENOV stock traded up $0.81 on Friday, reaching $46.38. The stock had a trading volume of 467,648 shares, compared to its average volume of 582,621. Enovis Co. has a 12 month low of $38.27 and a 12 month high of $65.03. The firm has a market capitalization of $2.59 billion, a price-to-earnings ratio of -21.12 and a beta of 1.91. The firm's 50-day moving average is $42.33 and its two-hundred day moving average is $45.33. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40.

Enovis (NYSE:ENOV - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.73 EPS for the quarter, topping analysts' consensus estimates of $0.62 by $0.11. The firm had revenue of $505.22 million during the quarter, compared to analysts' expectations of $504.44 million. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The company's revenue for the quarter was up 21.0% compared to the same quarter last year. During the same period in the previous year, the business posted $0.56 earnings per share. On average, research analysts expect that Enovis Co. will post 2.79 EPS for the current fiscal year.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.